Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPIRIT trial of imatinib dose and imatinib plus peginterferon alfa-2a in newly diagnosed chronic-phase chronic myeloid leukemia
ISRCTN59346371Phase 3Completed
- Sponsor
- Newcastle Hospitals NHS Foundation Trust
- Start
- Jun 2005
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of imatinib and interferon alfa in chronic myelogenous leukemia (CML) (3 arms), sponsored by Newcastle Hospitals NHS Foundation Trust. Primary endpoint: Overall survival at 5 years. Started Jun 2005; status: completed.
02
Drugs
imatinibinterferon alfa
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on ISRCTN59346371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN59346371.